Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

LEUPROLIDE ACETATE

Form:

11 of 11 products shown

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (L02A, L02AE) — coverage varies; not interchangeable

  • Buserelin (Suprefact Depot 2 Months): general benefit
  • Goserelin (Zoladex): general benefit
  • Triptorelin (Trelstar (1 Month)): general benefit
  • Megestrol (Megace): general benefit, Not a benefit

Lupron Depot PDS · DIN 00884502 · 3.75mg · injection-Kit

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Lupron Depot PDS · DIN 00884502 Manufacturer: Abbott Laboratories Limited; listing date 1996-10-01 Health Canada: Marketed since 2013-12-01 · brand LUPRON DEPOT · ATC L02AE02 LEUPRORELIN · form Powder for suspension (sustained-release · route Intramuscular · ingredients LEUPROLIDE ACETATE 3.75 MG/SYR · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Lupron Depot PDS: Formulary list price $404.6952/unit (unit not stated in source; not the patient's cost)

Ministry pays: $404.6952 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13443 · Verify on the e-Formulary ↗ (DIN 00884502)

Source record
DIN 00884502: Lupron Depot PDS Raw flags: sec3=Y Item: 100000084; group id 170; item number 0287; lccId None; manufacturer id ABB Source form: Inj-Kit; strength: 3.75mg Recorded listing: General benefit Source prices (unrounded): $404.6952; ministry $404.6952 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00884502 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13443
Shortage status: resolved shortage (ended 2021-01-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00884502
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Zeulide Depot · DIN 02429977 · 3.75mg/Vial · Pd for injection - vial

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Zeulide Depot · DIN 02429977 Manufacturer: Verity Pharmaceuticals Inc.; listing date 2020-05-29 Health Canada: Marketed since 2019-10-08 · brand ZEULIDE DEPOT · ATC L02AE02 LEUPRORELIN · form Powder for suspension (sustained-release, Kit · route Intramuscular · ingredients LEUPROLIDE ACETATE 3.75 MG/VIAL · company Verity pharmaceuticals inc. · schedule Prescription
Check this DIN again · Health Canada product record

Zeulide Depot: Formulary list price $304.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $304.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91439 · Verify on the e-Formulary ↗ (DIN 02429977)

Source record
DIN 02429977: Zeulide Depot Raw flags: sec3=Y Item: 100000310; group id 170; item number 0292; lccId None; manufacturer id VET Source form: Pd for Inj - Vial Pk; strength: 3.75mg/Vial Recorded listing: General benefit Source prices (unrounded): $304.0000; ministry $304.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02429977 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91439
Shortage status: active shortage (reported not recorded, last updated 2025-08-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02429977
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lupron Depot PDS · DIN 00836273 · 7.5mg · injection-Kit

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Lupron Depot PDS · DIN 00836273 Manufacturer: Abbott Laboratories Limited; listing date 1996-10-01 Health Canada: Marketed since 2013-12-11 · brand LUPRON DEPOT · ATC L02AE02 LEUPRORELIN · form Powder for suspension (sustained-release · route Intramuscular · ingredients LEUPROLIDE ACETATE 7.5 MG/SYR · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Lupron Depot PDS: Formulary list price $387.9700/unit (unit not stated in source; not the patient's cost)

Ministry pays: $387.9700 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10318 · Verify on the e-Formulary ↗ (DIN 00836273)

Source record
DIN 00836273: Lupron Depot PDS Raw flags: sec3=Y Item: 100000066; group id 170; item number 0288; lccId None; manufacturer id ABB Source form: Inj-Kit; strength: 7.5mg Recorded listing: General benefit Source prices (unrounded): $387.9700; ministry $387.9700 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00836273 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10318
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00836273
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Eligard · DIN 02248239 · 7.5mg · Pd suspension injection-pre-filled syringe Kit

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Eligard · DIN 02248239 Manufacturer: Tolmar International Ltd.; listing date 2004-07-20 Health Canada: Marketed since 2022-05-30 · brand ELIGARD · ATC L02AE02 LEUPRORELIN · form Powder for suspension (sustained-release · route Subcutaneous · ingredients LEUPROLIDE ACETATE 7.5 MG/SYR · company Tolmar international ltd. · schedule Prescription
Check this DIN again · Health Canada product record

Eligard: Formulary list price $310.7200/unit (unit not stated in source; not the patient's cost)

Ministry pays: $310.7200 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72576 · Verify on the e-Formulary ↗ (DIN 02248239)

Source record
DIN 02248239: Eligard Raw flags: sec3=Y Item: 100000172; group id 170; item number 0294; lccId None; manufacturer id TOL Source form: Pd Susp Inj-Pref Syr Kit; strength: 7.5mg Recorded listing: General benefit Source prices (unrounded): $310.7200; ministry $310.7200 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248239 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72576
Shortage status: resolved shortage (ended 2023-09-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248239
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lupron Depot PDS · DIN 02239834 · 11.25mg · injection-Kit

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Lupron Depot PDS · DIN 02239834 Manufacturer: Abbott Laboratories Limited; listing date 2000-07-17 Health Canada: Marketed since 2013-11-04 · brand LUPRON DEPOT · ATC L02AE02 LEUPRORELIN · form Powder for suspension (sustained-release · route Intramuscular · ingredients LEUPROLIDE ACETATE 11.25 MG/SYR · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Lupron Depot PDS: Formulary list price $1205.8956/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1205.8956 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63321 · Verify on the e-Formulary ↗ (DIN 02239834)

Source record
DIN 02239834: Lupron Depot PDS Raw flags: sec3=Y Item: 100000148; group id 170; item number 0289; lccId None; manufacturer id ABB Source form: Inj-Kit; strength: 11.25mg Recorded listing: General benefit Source prices (unrounded): $1205.8956; ministry $1205.8956 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239834 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63321
Shortage status: resolved shortage (ended 2021-03-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239834
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lupron Depot PDS · DIN 02230248 · 22.5mg · injection-Kit

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Lupron Depot PDS · DIN 02230248 Manufacturer: Abbott Laboratories Limited; listing date 1997-08-28 Health Canada: Marketed since 2013-12-09 · brand LUPRON DEPOT · ATC L02AE02 LEUPRORELIN · form Powder for suspension (sustained-release · route Intramuscular · ingredients LEUPROLIDE ACETATE 22.5 MG/SYR · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Lupron Depot PDS: Formulary list price $1071.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1071.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=48922 · Verify on the e-Formulary ↗ (DIN 02230248)

Source record
DIN 02230248: Lupron Depot PDS Raw flags: sec3=Y Item: 100000113; group id 170; item number 0290; lccId None; manufacturer id ABB Source form: Inj-Kit; strength: 22.5mg Recorded listing: General benefit Source prices (unrounded): $1071.0000; ministry $1071.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230248 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=48922
Shortage status: resolved shortage (ended 2020-12-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230248
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Eligard · DIN 02248240 · 22.5mg · Pd suspension injection-pre-filled syringe Kit

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Eligard · DIN 02248240 Manufacturer: Tolmar International Ltd.; listing date 2004-07-20 Health Canada: Marketed since 2022-03-25 · brand ELIGARD · ATC L02AE02 LEUPRORELIN · form Powder for suspension (sustained-release · route Subcutaneous · ingredients LEUPROLIDE ACETATE 22.5 MG/SYR · company Tolmar international ltd. · schedule Prescription
Check this DIN again · Health Canada product record

Eligard: Formulary list price $891.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $891.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72577 · Verify on the e-Formulary ↗ (DIN 02248240)

Source record
DIN 02248240: Eligard Raw flags: sec3=Y Item: 100000173; group id 170; item number 0295; lccId None; manufacturer id TOL Source form: Pd Susp Inj-Pref Syr Kit; strength: 22.5mg Recorded listing: General benefit Source prices (unrounded): $891.0000; ministry $891.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248240 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72577
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248240
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Zeulide Depot · DIN 02462699 · 22.5mg/Vial · Pd for injection - vial

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Zeulide Depot · DIN 02462699 Manufacturer: Verity Pharmaceuticals Inc.; listing date 2020-05-29 Health Canada: Marketed since 2019-10-08 · brand ZEULIDE DEPOT · ATC L02AE02 LEUPRORELIN · form Kit, Powder for suspension (sustained-release · route Intramuscular · ingredients LEUPROLIDE ACETATE 22.5 MG/VIAL · company Verity pharmaceuticals inc. · schedule Prescription
Check this DIN again · Health Canada product record

Zeulide Depot: Formulary list price $873.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $873.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95052 · Verify on the e-Formulary ↗ (DIN 02462699)

Source record
DIN 02462699: Zeulide Depot Raw flags: sec3=Y Item: 100000311; group id 170; item number 0293; lccId None; manufacturer id VET Source form: Pd for Inj - Vial Pk; strength: 22.5mg/Vial Recorded listing: General benefit Source prices (unrounded): $873.0000; ministry $873.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02462699 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95052
Shortage status: resolved shortage (ended 2025-08-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02462699
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lupron Depot PDS · DIN 02239833 · 30mg · injection-Kit

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Lupron Depot PDS · DIN 02239833 Manufacturer: Abbott Laboratories Limited; listing date 2000-04-17 Health Canada: Marketed since 2013-12-17 · brand LUPRON DEPOT · ATC L02AE02 LEUPRORELIN · form Powder for suspension (sustained-release · route Intramuscular · ingredients LEUPROLIDE ACETATE 30 MG/SYR · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Lupron Depot PDS: Formulary list price $1428.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1428.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63320 · Verify on the e-Formulary ↗ (DIN 02239833)

Source record
DIN 02239833: Lupron Depot PDS Raw flags: sec3=Y Item: 100000146; group id 170; item number 0291; lccId None; manufacturer id ABB Source form: Inj-Kit; strength: 30mg Recorded listing: General benefit Source prices (unrounded): $1428.0000; ministry $1428.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239833 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63320
Shortage status: resolved shortage (ended 2021-03-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239833
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Eligard · DIN 02248999 · 30mg · Pd suspension injection-pre-filled syringe Kit

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Eligard · DIN 02248999 Manufacturer: Tolmar International Ltd.; listing date 2005-05-25 Health Canada: Marketed since 2022-04-08 · brand ELIGARD · ATC L02AE02 LEUPRORELIN · form Powder for suspension (sustained-release · route Subcutaneous · ingredients LEUPROLIDE ACETATE 30 MG/SYR · company Tolmar international ltd. · schedule Prescription
Check this DIN again · Health Canada product record

Eligard: Formulary list price $1285.2000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1285.2000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73384 · Verify on the e-Formulary ↗ (DIN 02248999)

Source record
DIN 02248999: Eligard Raw flags: sec3=Y Item: 100000176; group id 170; item number 0296; lccId None; manufacturer id TOL Source form: Pd Susp Inj-Pref Syr Kit; strength: 30mg Recorded listing: General benefit Source prices (unrounded): $1285.2000; ministry $1285.2000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248999 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73384
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248999
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Eligard · DIN 02268892 · 45mg · Pd suspension injection-pre-filled syringe Kit

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Eligard · DIN 02268892 Manufacturer: Tolmar International Ltd.; listing date 2006-06-15 Health Canada: Marketed since 2022-04-22 · brand ELIGARD · ATC L02AE02 LEUPRORELIN · form Powder for suspension (sustained-release · route Subcutaneous · ingredients LEUPROLIDE ACETATE 45 MG/SYR · company Tolmar international ltd. · schedule Prescription
Check this DIN again · Health Canada product record

Eligard: Formulary list price $1659.9000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1659.9000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75428 · Verify on the e-Formulary ↗ (DIN 02268892)

Source record
DIN 02268892: Eligard Raw flags: sec3=Y Item: 100000181; group id 170; item number 0297; lccId None; manufacturer id TOL Source form: Pd Susp Inj-Pref Syr Kit; strength: 45mg Recorded listing: General benefit Source prices (unrounded): $1659.9000; ministry $1659.9000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02268892 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75428
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02268892
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

GOSERELIN ACETATE

· 2 products · General benefit · strengths: 3.6mg, 10.8mg · Depot Inj

TRIPTORELIN PAMOATE

· 5 products · General benefit · strengths: 3.75mg/Vial, 11.25mg/Vial, 22.5mg/Vial · Inj Pd with Sterile Water-Vial Pk, Inj Pd-Vial Pk, SR Inj Pd with Sterile Water-Vial Pk

MEGESTROL ACETATE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 40mg, 160mg · Tab

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

ANASTROZOLE

· 17 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab

CAPECITABINE

· 15 products · General benefit · strengths: 150mg, 500mg · Tab

CHLORAMBUCIL

· 1 products · General benefit · strengths: 2mg · Tab

CYCLOPHOSPHAMIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg, 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: endometriosis
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: GOSERELIN ACETATE GOSERELIN ACETATE · General benefit COPYRIGHT 2017 TERSERA THERAPEUTICS LLC Page 3 of 45 Benign Conditions  ZOLADEX is indicated for the hormonal management of endometriosis, including pain relief and reduction of endometriotic lesions. PM: https://pdf.hres.ca/dpd_pm/00042728.PDF; date December 21, 2017; DIN 02049325; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS LUPRON DEPOT (leuprolide acetate for extended-release injectable suspension) must be administered by a healthcare professional. Central Precocious Puberty (CPP) LUPRON DEPOT 3.75 mg (1-Month) and 7.5 mg (1-Month) are indicated for: • the treatment of children with central precocious puberty (CPP). Children should be selected using the following criteria: 1. Clinical diagnosis of CPP (idiopathic or neurogenic) with onset of secondary sexual characteristics earlier than 8 years in females and 9 years in males. 2. Clinical diagnosis should be confirmed prior to initiation of therapy as follows: a) Confirmation of diagnosis by a pubertal response to a gonadotropin-releasing hormone (GnRH) stimulation test. The sensitivity and methodology of this assay must be understood. b) Bone age advanced one year beyond the chronological age. 3. Baseline evaluation should also include: a) Height and weight measurements b) Sex steroid levels c) Adrenal steroid level to exclude congenital adrenal hyperplasia d) Beta human chorionic gonadotropin level to rule out a chorionic gonadotropin s… https://pdf.hres.ca/dpd_pm/00082398.PDF PM date: 2025-11-13 Source product: LUPRON DEPOT; DIN 00836273; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Zeulide Depot · DIN 02429977 Shortage status: active shortage (reported not recorded, last updated 2025-08-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02429977

Check this DIN again